MAP2K7 and ovarian neoplasm: As pERK is overexpressed in approximately one-third of primary ovarian tumours and 65% of tumour samples from primary chemo-resistant tumours obtained after chemotherapy, treatment of patients with Ras/Raf/MEK/Erk-targeted agents appears to be an interesting therapeutic option (Messersmith et al, 2006).